Mikael Anttinen

7PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersBiomedical imagingMedical infection agents (incl. prions)Medical molecular engineering of nucleic acids and proteinsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 25, 2026
Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer.

|May 28, 2025
Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.

Antti Viitala, Mikael Anttinen, Pietari Mäkelä

|Mar 30, 2025
Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer.

Aino Kivikallio, Simona Malaspina, Irena Saarinen

|Jan 30, 2023
Deep learning prediction of non-perfused volume without contrast agents during prostate ablation therapy.

Cameron Wright, Pietari Mäkelä, Alexandre Bigot

|Sep 08, 2020
Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer.

Mikael Anttinen, Pietari Mäkelä, Pertti Nurminen

|Sep 27, 2019
Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer.

Mikael Anttinen, Pietari Mäkelä, Visa Suomi

Pageof 2

Frequent Collaborators

3 joint publications

Visa Suomi

3 joint publications

Peter J Boström

3 joint publications

Pekka Taimen

2 joint publications

Pietari Mäkelä